Business Context and Reporting Period
Company: Intrexon Corporation (Note: Metadata referenced Precigen, Inc., but the filing is by Intrexon Corporation regarding its subsidiary Precigen, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2018
Event: Entry into a Material Definitive Agreement (Securities Purchase, Assignment and Assumption Agreement) with ARES TRADING S.A. ("ARES") and Precigen, Inc.
Key Financial Metrics and Transaction Terms
- Transaction Value: Intrexon will issue common stock with a value equal to $150,000,000 to ARES.
- Convertible Note: Intrexon and Precigen will issue a convertible note with an original principal amount of $25,000,000.
- Note Terms: 5% annual interest rate; matures 30 months post-closing; unsecured.
- Commitment: At least $25,000,000 (the note amount) committed to advancing Precigen therapeutic programs.
- Royalties: Intrexon agreed to pay ARES a 10% royalty on net sales of two specified CAR-T products and a 10% royalty on sublicensing fees for related IP.
- Lock-Up Period: ARES is subject to an 180-day lock-up period on issued shares.
Material Changes and Agreements
Intrexon assumed all rights and obligations of ARES under a 2015 License and Collaboration Agreement with ZIOPHARM Oncology, Inc. The transaction involves the issuance of unregistered equity securities and a convertible note. If the aggregate issuance exceeds 19.99% of outstanding common stock, Intrexon must seek shareholder approval; otherwise, it must pay cash equal to the value of the excess shares.
Outlook, Risks, and Contingencies
- Closing Conditions: Expected to close as soon as December 28, 2018, subject to Hart-Scott-Rodino Antitrust clearance and other customary conditions.
- Termination: Either party may terminate for material breach or if the transaction does not close by March 31, 2019.
- Conversion Mechanics: The Convertible Note may convert into Intrexon Common Stock or Precigen equity upon qualified financings. Automatic conversion into Common Stock occurs on the second anniversary if not previously converted.
- Regulatory Disclosure: The press release announcing the agreement was issued on December 20, 2018.
Investor Verification Checklist
- Verify the final closing date and confirmation of Hart-Scott-Rodino clearance.
- Confirm the exact number of shares issued based on the 10-day volume-weighted average price calculation.
- Monitor whether the issuance exceeds the 19.99% threshold requiring shareholder approval or triggering a cash payment alternative.
- Review the full text of the Convertible Note and Purchase Agreement filed as exhibits to the 2018 Form 10-K for detailed covenants and default provisions.
- Assess the impact of the 10% royalty obligation on future margins for the specified CAR-T products.